Royalty Pharma Q4 2020 Earnings Report
Key Takeaways
Royalty Pharma's Q4 2020 results showed an 18% increase in net cash provided by operating activities and a 9% increase in Adjusted Cash Receipts. The company also announced $2.4 billion in acquisitions for 2020 and increased its outlook for 2020-2025 Adjusted Cash Receipts CAGR to 7%-10%.
Net cash provided by operating activities increased by 18% in Q4 2020.
Adjusted Cash Receipts grew by 9% to $484 million in Q4 2020.
Adjusted Cash Flow increased by 22% to $423 million in Q4 2020.
The company executed $2.4 billion of transactions spanning five therapeutic areas in 2020.
Royalty Pharma
Royalty Pharma
Forward Guidance
Royalty Pharma anticipates full-year 2021 Adjusted Cash Receipts(1) to be between $1,910 million and $1,960 million, excluding new transactions announced subsequent to the date of this release.